Atlas Trials

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT01064401 · COMPLETED

Trial details

NCT number
NCT01064401
Sponsor
Biogen
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsing-Remitting Multiple Sclerosis
Start date
2010-05-01
Primary completion
2014-03-01
Enrollment
1841

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.